INmune Bio Inc.

Key Points from the article: "Inflammaging, a chronic low-grade inflammation, is associated with an increased risk of heart attack, cancer, Alzheimer's and other conditions. It occurs as we age, but some people develop it more than others. Chronic inflammation can be caused by cellular senescence, where damaged aging cells secrete inflammatory proteins. Prevention and treatment measures include lifestyle changes such as exercise, healthy diet and adequate sleep."

On Tuesday, February 13th at 10:30AM, we are pleased that Joel Beatty, MD, CFA of Baird is hosting a Discovery Series to share the unique trial design of our Phase 2 program and why #neuroinflammation is important in Alzheimer's. Christopher (CJ) Barnum PhD, Malú Gámez Tansey and RJ Tesi will cover key topics – first, they will provide an update on the unique features of the Company’s ongoing blinded, randomized, placebo-controlled Phase II trial for Early Alzheimer's disease (MCI/Mild AD). Additionally, the group will highlight the role and consequences of neuroinflammation and how #Xpro1595 in neutralizing soluble TNF and preserving transmembrane TNF function decreased neuroinflammation (decreased inflammatory cytokines in the CFS and decrease White Matter Free Water in white matter tracts), decreased neurodegeneration (46% decrease in pTau217; 84% decrease in NFL), improved synaptic function and promoted remyelination of axons in our Phase 1 program. To register: https://lnkd.in/eH22iyMP

Excited to share this series on #AlzheimersDisease on the Novonordisk science hub that includes a video conversation on #central and #peripheral #immunecrosstalk #inflammation & #immunity in AD with my rockstar colleague Cynthia Lemere Harvard Medical School https://lnkd.in/eYpxWpXs

My late parents showed signs of early Alzheimer’s before they passed at 90 and I have friends with family members who struggle with this condition. Investor's Business Daily 's #biotech reporter Allison Gatlin does a great job explaining why there may be hope in the near future with the new #Alzheimer’s drugs from Biogen , Eisai US and Eli Lilly and Company which have caused a stir in the biotech and pharma industry. "The beautiful thing about the fact those drugs got approved is it's the first time you had a disease-modifying drug," INmune Bio Inc. co-founder and CFO David Moss told Investor's Business Daily. "It opens the door for investment for companies like us. Now we've shown there's a light at the end of the tunnel." Prothena Corporation CEO Gene Kinney also told IBD: "I think it's an incredibly exciting time. I do believe these advances in medicine will help move the field forward." https://lnkd.in/gz2dFAPE

I couldn't agree more with the title of this article from Investor's Business Daily penned by Allison Gatlin. Complex diseases such as #alzheimersdisease require a complex approach and we are at the tip of the iceberg when it comes to therapies for this dreadful disease. We appreciate the support of the community in trying novel approaches and we truly believe that we are at the start of a revolutionary process in the treatment of #alzheimers and many other neurodegenerative diseases.